Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Respiratory syncytial virus and influenza activity are on the rise in parts of the country, particularly among young children, according to the CDC's latest respiratory virus updates. Overall, the ...

as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

What if infections of respiratory syncytial virus, known as R.S.V., peak at unusual levels, as they did in the 2022-23 season? What if the new strain of mpox, which is especially virulent ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

As the weather gets colder, respiratory viruses become more common. Illnesses like influenza, COVID-19 and respiratory syncytial virus pose the risk of severe outcomes, such as hospitalization and ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.